<DOC>
	<DOCNO>NCT01839331</DOCNO>
	<brief_summary>This study evaluate efficacy two dose Intra-Articular Injection Ampion™ Adults pain due osteoarthritis knee .</brief_summary>
	<brief_title>AP-003-A A Efficacy Safety Study Two Doses Intra-Articular Injection Ampion™ Adults With Pain Due Osteoarthritis Knee</brief_title>
	<detailed_description>A Randomized , Placebo-controlled , Double-Blind Study Evaluate Efficacy Safety two Doses Intra-Articular Injection Ampion™ Adults pain due osteoarthritis knee . The primary trial objective evaluate great efficacy 10 mL Ampion™ versus 10 mL placebo 4 mL Ampion™ versus 4 mL placebo intra-articular ( IA ) injection improve knee pain , apply patient suffer OA knee . The secondary trial objective include : evaluation safety intra-articular injection Ampion™ apply patient suffer OA knee , evaluation efficacy intra-articular injection Ampion™ placebo stiffness function apply patient suffer OA knee evaluation responder status define Outcome Measures Rheumatology Clinical Trials Osteoarthritis Research Society International ( OMERACT-OARSI ) Criteria .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Able provide write informed consent participate study Willing able comply study requirement instruction site study staff Male female , 40 year 85 year old ( inclusive ) Must ambulatory Index knee must symptomatic great 6 month clinical diagnosis OA support radiological evidence Kellgren Lawrence Grade II IV ) old 6 month prior date screen Moderate moderatelysevere OA pain index knee ( rating least 1.5 WOMAC Index 3.1 5point Likert Pain Subscale ) assess screen Moderate moderatelysevere OA pain index knee ( even chronic dos nonsteroidal antiinflammatory drug ( NSAID ) , change 4 week prior screen , been/are use ) No analgesia ( include acetaminophen [ paracetamol ] ) take 12 hour prior efficacy measure No know clinically significant liver abnormality e.g . cirrhosis , transplant , etc . ) As result medical review screen investigation , Principal Investigator consider patient unfit study A history allergic reaction human albumin ( reaction nonhuman albumin egg albumin exclusion criterion ) A history allergic reaction excipients 5 % human albumin ( Nacetyltryptophan , sodium caprylate ) Presence tense effusion Inflammatory crystal arthropathy , acute fracture , history aseptic necrosis joint replacement affect knee , assess locally Principal Investigator Isolated patella femoral syndrome , also know chondromalacia Any disease condition interfere free use evaluation index knee duration trial e.g . cancer , congenital defect , spine OA ) Major injury index knee within 12 month prior screen Severe hip OA ipsilateral index knee Any pain could interfere assessment index knee pain ( e.g . pain part low extremity , pain radiate knee ) Any pharmacological nonpharmacological treatment target OA start change 4 week prior randomization likely change duration study Use follow medication : 1 . No IA inject pain medication study knee study 2 . No analgesic contain opioids . NSAIDs may continue level precede study acetaminophen available rescue medication study provide supply 3 . No topical treatment osteoarthritis index knee study 4 . No significant anticoagulant therapy ( e.g . Heparin Lovenox ) study ( treatment Aspirin Plavix allow ) 5 . No systemic treatment may interfere safety efficacy assessment study 6 . No immunosuppressant 7 . No use corticosteroids &gt; 10 mg prednisolone equivalent per day ( ≤ 10 mg prednisolone , dose must stable ) Any human albumin treatment 3 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>osteoarthrisis knee</keyword>
</DOC>